Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059384 · ClinicalTrials.gov registry record · Phase 4
Alternative Dosing Strategy for Anti-HIV Drugs
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT00059384 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 66 participants.
The verdict
NCT00059384, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
Anti-HIV drugs are usually given to patients at fixed, standardized doses. This study will investigate alternative ways of dosing anti-HIV drugs to improve viral control. Study hypothesis: The optimal dosage regimen required to obtain the maximum benefit from antiretroviral therapy is achieved with strategies that control for pharmacokinetic and pharmacodynamic variability among patients.
Interventions
- BEHAVIORAL Concentration-controlled therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059384
The ClinicalTrials.gov registry entry for NCT00059384 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Concentration-controlled therapy is the first listed.
NCT00059384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059384 about?
NCT00059384 is a clinical study titled "Alternative Dosing Strategy for Anti-HIV Drugs". Anti-HIV drugs are usually given to patients at fixed, standardized doses. This study will investigate alternative ways of dosing anti-HIV drugs to improve viral control. Study hypothesis: The optimal dosage regimen required to obtain the maximum benefit from antiretroviral therapy is achieved with...
What is the current status of trial NCT00059384?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2003-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00059384?
The interventions under investigation include: Concentration-controlled therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00059384?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.